The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
TALAPRO-3: Talazoparib (TALA) + enzalutamide (ENZA) compared with placebo (PBO) + ENZA for the treatment of patients (pts) with metastatic castration-sensitive prostate cancer (mCSPC) harboring homologous recombination repair (HRR) gene alterations.
 
Neeraj Agarwal
Research Funding - Amgen (Inst); Arvinas (Inst); AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Calithera Biosciences (Inst); Celldex (Inst); crispr therapeutics (Inst); Eisai (Inst); Exelixis (Inst); Genentech (Inst); Gilead Sciences (Inst); Immunomedics (Inst); Janssen (Inst); Lilly (Inst); Merck (Inst); Nektar (Inst); ORIC Pharmaceuticals (Inst); ORIC Pharmaceuticals (Inst); Pfizer (Inst); Takeda (Inst)
Travel, Accommodations, Expenses - Exelixis; Pfizer
 
Nobuaki Matsubara
Honoraria - Sanofi
Consulting or Advisory Role - Amgen; AstraZeneca; Janssen; Lilly; Pfizer; Sanofi; Seagen
Research Funding - Abbvie (Inst); Amgen (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Bayer (Inst); Bayer Yakuhin (Inst); Bristol-Myers Squibb Japan (Inst); Chugai Pharma (Inst); Eisai (Inst); Janssen (Inst); Lilly (Inst); MSD (Inst); Novartis (Inst); Roche/Genentech (Inst); Seagen (Inst); Takeda (Inst)
 
Arun Azad
Honoraria - Aculeus Therapeutics; Amgen; Astellas Pharma; AstraZeneca; Bayer; Bristol-Myers Squibb; Daiichi Sankyo; Ipsen; Janssen; Merck Serono; Merck Sharp & Dohme; Novartis; Noxopharm; Pfizer; Sanofi; Telix Pharmaceuticals; Tolmar
Consulting or Advisory Role - Aculeus Therapeutics; Amgen; Astellas Pharma; AstraZeneca; Bayer; Bristol-Myers Squibb; Daiichi Sankyo; Ipsen; Janssen; Merck Serono; Merck Sharp & Dohme; Novartis; Noxopharm; Pfizer; Sanofi; Telix Pharmaceuticals; Tolmar
Speakers' Bureau - Amgen; Astellas Pharma; Bayer; Bristol-Myers Squibb; Ipsen; Janssen; Merck Serono; Novartis
Research Funding - Aptevo Therapeutics (Inst); Astellas Pharma; Astellas Pharma (Inst); AstraZeneca; AstraZeneca (Inst); Bionomics (Inst); Bristol-Myers Squibb (Inst); Exelixis (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); Hinova Pharmaceuticals (Inst); Ipsen (Inst); Janssen (Inst); Lilly (Inst); MedImmune (Inst); Merck Serono; Merck Serono (Inst); MSD (Inst); Novartis (Inst); Pfizer (Inst); Sanofi (Inst); Synthorx (Inst)
Travel, Accommodations, Expenses - Amgen; Astellas Pharma; Bayer; Hinova Pharmaceuticals; Janssen; Merck Serono; Pfizer; Sanofi; Tolmar
 
Fred Saad
Honoraria - Abbvie; Advanced Accelerator Applications; Astellas Pharma; AstraZeneca; Bayer; BMS; GlaxoSmithKline; Janssen Oncology; Knight Therapeutics; Merck; Myovant Sciences; Novartis; Pfizer; Sanofi; Sumitomo Dainippon Pharma Oncology; Tolmar
Consulting or Advisory Role - Abbvie; Advanced Accelerator Applications; Astellas Pharma; AstraZeneca/MedImmune; Bayer; GlaxoSmithKline; Janssen Oncology; Knight Therapeutics; Myovant Sciences; Novartis; Pfizer; Sanofi; Sumitomo Dainippon Pharma Oncology; Tolmar
Research Funding - Abbvie (Inst); Advanced Accelerator Applications (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Janssen Oncology (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst); Point Therapeutics (Inst); Sanofi (Inst)
 
Joaquin Mateo
Consulting or Advisory Role - Amunix; AstraZeneca; Daiichi Sankyo Europe GmbH; Illumina; MSD; Nuage Therapeutics; Pfizer
Speakers' Bureau - AstraZeneca; Guardant Health; Janssen; Pfizer
Research Funding - Amgen (Inst); AstraZeneca (Inst); Pfizer (Inst)
Other Relationship - Nuage Therapeutics
 
Shusuan Jiang
No Relationships to Disclose
 
Dingwei Ye
No Relationships to Disclose
 
Eric Voog
No Relationships to Disclose
 
Neal Shore
Stock and Other Ownership Interests - Photocure
Consulting or Advisory Role - Accord Research; Alessa Therapeutics; Amgen; Antev; Asieris Pharmaceuticals; Astellas Pharma; AstraZeneca; Aura Biosciences; Bayer; Bioprotect; Bristol-Myers Squibb/Sanofi; CG Oncology; Clarity Pharmaceuticals; Dendreon; Exact Imaging; Ferring; Fize Medical; Glytherix; ImmunityBio; InVitae; Janssen Scientific Affairs; Lantheus Medical Imaging; Lilly; MDxHealth; Medivation/Astellas; Merck; Minomic; Myriad Genetics; Novartis; Nusano; Pfizer; Photocure; PlatformQ Health; Promaxo; Protara Therapeutics; Sanofi; Siemens; Speciality Networks; Sumitomo Pharma Oncology; Telix Pharmaceuticals; Tolmar; Tutelix; Urogen pharma
Research Funding - Abbvie; Advantagene; Amgen; Aragon Pharmaceuticals; Astellas Pharma; AstraZeneca; Bayer; Boston Scientific; Bristol-Myers Squibb/Pfizer; CG Oncology; Clovis Oncology; Dendreon; DisperSol; Endocyte; Exact Imaging; Exelixis; Ferring; FKD Therapies; FORMA Therapeutics; Foundation Medicine; Genentech; Guardant Health; InVitae; Istari Oncology; Janssen; Jiangsu Yahong Meditech; MDxHealth; Medivation; Merck; MT Group; Myovant Sciences; Myriad Genetics; Novartis; Nymox; OncoCellMDx; ORIC Pharmaceuticals; pacific edge; Palette Life Sciences; Pfizer; Plexxikon; POINT Biopharma; Propella Therapeutics; Propella Therapeutics; RhoVac; Sanofi; SeaGen; Sesen Bio; Steba Biotech; Theralase; Tolmar; Urogen pharma; Urotronic; US Biotest; Vaxiion; Veru; Zenflow
 
Timucin Cil
Consulting or Advisory Role - AstraZeneca; BMS Turkey; Merck
Speakers' Bureau - Lilly; Pfizer; Takeda
 
Christof Vulsteke
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Atheneum; Bayer; Bristol-Myers Squibb/Pfizer; GlaxoSmithKline; ipsen; Janssen; LEO Pharma; MSD; Pfizer
Research Funding - MSD (Inst)
Travel, Accommodations, Expenses - Roche
 
Hsiao-Jen Chung
No Relationships to Disclose
 
Stefanie Zschaebitz
Honoraria - Amgen; Astellas Pharma; Bayer; BMS GmbH & Co. KG; Eisai Germany; Ipsen; Janssen Oncology; Merck Serono; MSD Oncology; Novartis; Pfizer (Inst)
Consulting or Advisory Role - Amgen; Astellas Pharma (Inst); AstraZeneca; Bayer (Inst); Bristol-Myers Squibb (Inst); Eisai; EUSA Pharma; Gilead Sciences; Ipsen; Merck; MSD Oncology; Pfizer (Inst); Roche; Sanofi/Aventis (Inst)
Research Funding - Eisai (Inst)
Travel, Accommodations, Expenses - Amgen; Astellas Pharma; AstraZeneca; BMS GmbH & Co. KG; Ipsen; Janssen Oncology; Merck; Pfizer
 
Douglas Laird
Employment - Pfizer
Stock and Other Ownership Interests - Pfizer
 
Xiaoxi Zhang
Employment - Pfizer
Stock and Other Ownership Interests - Pfizer
 
Prachi Nandoskar
Employment - Pfizer
Stock and Other Ownership Interests - Pfizer
 
Sarah Fenech Chetcuti
Employment - Pfizer
Stock and Other Ownership Interests - Pfizer
 
Fong Wang
Employment - Exelixis; Pfizer
Stock and Other Ownership Interests - Exelixis; Pfizer
Research Funding - Exelixis; Pfizer
Travel, Accommodations, Expenses - Exelixis; Pfizer
 
Karim Fizazi
Honoraria - Astellas Pharma (Inst); Bayer (Inst); Janssen (Inst); Novartis (Inst)
Consulting or Advisory Role - Amgen (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Daiichi Sankyo Europe GmbH (Inst); Janssen Oncology (Inst); MSD (Inst); Novartis (Inst); Pfizer (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Bayer; Janssen; MSD; Novartis; Pfizer